There are 2789 resources available
Q&A and live discussion
Presenter: Sherene Loi
Session: Proffered Paper session - Translational research
Resources:
Slides
Webcast
Introduction by the chair
Presenter: Omid Hamid
Session: Stay at the bench or move to the bedside: What is the role for neoadjuvant therapy in melanoma today?
Resources:
Slides
Webcast
Yes, ready for primetime in the clinic
Presenter: Paolo Ascierto
Session: Stay at the bench or move to the bedside: What is the role for neoadjuvant therapy in melanoma today?
Resources:
Slides
Webcast
No, appropriate for clinical trial/biomarker work at this time
Presenter: Reinhard Dummer
Session: Stay at the bench or move to the bedside: What is the role for neoadjuvant therapy in melanoma today?
Resources:
Slides
Webcast
Polling 2 (led by chair)
Presenter: Omid Hamid
Session: Stay at the bench or move to the bedside: What is the role for neoadjuvant therapy in melanoma today?
Resources:
Slides
Webcast
Q&A
Presenter: Omid Hamid
Session: Stay at the bench or move to the bedside: What is the role for neoadjuvant therapy in melanoma today?
Resources:
Slides
Webcast
LBA15 - Primary outcome of the phase III SYD985.002/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician’s choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer
Presenter: Cristina Saura Manich
Session: Proffered Paper session - Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
1123O - Evaluation of cell-free DNA approaches for multi-cancer early detection
Presenter: Minetta Liu
Session: Proffered Paper session - Translational research
Resources:
Abstract
Slides
Webcast
LBA4_PR - Abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men with high-risk non-metastatic (M0) prostate cancer (PCa): Combined analysis from two comparisons in the STAMPEDE platform protocol
Presenter: Gerhardt Attard
Session: Presidential symposium 2
Resources:
Abstract
Slides
Webcast
LBA5_PR - A phase III trial with a 2x2 factorial design in men with de novo metastatic castration-sensitive prostate cancer: Overall survival with abiraterone acetate plus prednisone in PEACE-1
Presenter: Karim Fizazi
Session: Presidential symposium 2
Resources:
Abstract
Slides
Webcast